痴呆
内科学
医学
糖尿病
碳水化合物代谢
内分泌学
胰岛素抵抗
阿尔茨海默病
疾病
生物标志物
糖代谢紊乱
荟萃分析
肿瘤科
生物
生物化学
作者
Veerle van Gils,Marianna Rizzo,Jade Côté,Wolfgang Viechtbauer,Giuseppe Fanelli,Jordi Salas‐Salvadó,Theresa Wimberley,Mònica Bulló,Fernando Fernández‐Aranda,Søren Dalsgaard,Pieter Jelle Visser,Willemijn J. Jansen,Stephanie J.B. Vos
标识
DOI:10.1016/j.neubiorev.2024.105604
摘要
Conflicting evidence exists on the relationship between diabetes mellitus (DM) and Alzheimer’s disease (AD) biomarkers. Therefore, we conducted a random-effects meta-analysis to evaluate the correlation of glucose metabolism measures (glycated haemoglobin, fasting blood glucose, insulin resistance indices) and DM status with AD biomarkers of amyloid-β and tau measured by positron emission tomography or cerebrospinal fluid. We selected 37 studies from PubMed and Embase, including 11,694 individuals. More impaired glucose metabolism and DM status were associated with higher tau biomarkers (r=0.11[0.03-0.18], p=0.008; I2=68%), but were not associated with amyloid-β biomarkers (r=-0.06[-0.13-0.01], p=0.08; I2=81%). Meta-regression revealed that glucose metabolism and DM were specifically associated with tau biomarkers in population settings (p=0.001). Furthermore, more impaired glucose metabolism and DM status were associated with lower amyloid-β biomarkers in memory clinic settings (p=0.004), and in studies with a higher prevalence of dementia (p<0.001) or lower cognitive scores (p=0.04). These findings indicate that DM is associated with biomarkers of tau but not with amyloid-β. This knowledge is valuable for improving dementia and DM diagnostics and treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI